Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: A comparison of simultaneous and alternating regimens

AIDS

Volumn 11, Issue 1, 1997, Pages 59-66

  Brouwers, Pim ^a   Hendricks, Michael ^a   Lietzau, Jill A ^a   Pluda, James M ^a   Mitsuya, Hiroaki ^a   Yarchoan, Samuel Broder Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiviral therapy; HIV dementia; Macrophages; Neuropsychological

Indexed keywords

DIDANOSINE; ZIDOVUDINE;

ADULT; AFFECT; ARTICLE; ATTENTION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINGUISTICS; MALE; MEMORY; MOOD; MOTOR PERFORMANCE; NEUROPSYCHOLOGY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; READING;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; ZIDOVUDINE;

EID: 0031026871     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199701000-00009     Document Type: Article

References (16)

1. American Academy of Neurology AIDS Task Force: Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 infection. Neurology 1991, 41:778-785.
2. Navin BA, Jordan BD, Price RW: The AIDS dementia complex: I. Clinical features. Ann Neurol 1986, 19:517-524.
3. Price RW, Brew B, Rosenblum M: The AIDS dementia complex and HIV-1 brain infection: a pathogenic model of virus-immune interaction. Res Publ Assoc Res Nerv Ment Dis 1990, 68:269-290.
4. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK: Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992, 42:1472-1476.
5. Brouwers P, Tudor-Williams G, DeCarli C, et al.: Relation between stage of disease and neurobehavioral measures in children with symptomatic HIV disease. AIDS 1995, 9:713-720.
6. Davis L, Hjelle BL, Miller VE, et al.: Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992, 42:1736-1739.
7. Shaw CM, Harper ME, Hahn BE, et al.: HTLV-III infection in brains of children and adults with AIDS. Science 1985, 227:177-182.
8. Koenig S, Gendelman HE, Orenstein JM, et .al.: Detection of AIDS virus in macrophage in brain tissue from AIDS patients with encephalopathy. Science 1986, 233:1089-1093.
9. Resnick L, diMarzo-Veronese F, Schupbach J, et al.: Intrablood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. N Engl J Med 1985, 313:1498-1504.
10. Epstein LG, Gendelman HE: Human immunodeficiency virus type 1 infection of the nervous system: pathogenic mechanisms. Ann Neural 1993, 33:429-436.
11. Yarchoan R, Berg G, Brouuers P, et al.: Response of human immunodeficiency virus-associated neurological disease to 3'azido-3'deoxythymidine. Lancet 1987, i:132-135.
12. Pizzo P, Eddy J, Falloon J, et al.: Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med 1988, 319:889-896.
13. Schmitt F, Bigley J, McKinnis R, Logue P, Evans R, Drucker J, AZT Collaboration Group: Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDSrelated complex. N Engl I Med 1988, 319:1573-1578.
14. Schmitt FA, Dickson LR, Brouwers P: Neuropsychological response to antirelroviral therapy in HIV infection. In Neuropsychology of HIV Infection. Edited by Grant I, Martin A. New York: Oxford University Press; 1994:276-294.
15. Sidtis JJ, Gatsonis C, Price RW: Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. Ann Neural 1993, 33:343-349.
16. Yarchoan R, Pluda JM, Thomas RV, et al.: Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990, 336:526-529.